{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"17"}],"units":"Participants"}],"groups":[{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"BG000","title":"Dose Escalation: 3 x 10^7 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"BG001","title":"Dose Escalation: 1 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"BG002","title":"Dose Escalation: 3 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^9 autologous anti-BCMA CAR T cells on Day 0.","id":"BG003","title":"Dose Escalation: 1 x 10^9 KITE-585"},{"description":"RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \\[Grade 2 chronic kidney disease\\]) received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 24 mg/m\\^2/day IV infusion for 3 days followed by single infusion of KITE-585 at a tolerable dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"BG004","title":"Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"14"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"50","upperLimit":"56","value":"52.3"},{"groupId":"BG001","lowerLimit":"49","upperLimit":"71","value":"59.8"},{"groupId":"BG002","lowerLimit":"49","upperLimit":"67","value":"59.3"},{"groupId":"BG003","lowerLimit":"47","upperLimit":"58","value":"54.3"},{"groupId":"BG004","lowerLimit":"47","upperLimit":"65","value":"56.3"},{"groupId":"BG005","lowerLimit":"47","upperLimit":"71","value":"56.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"7"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"10"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"16"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"13"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The Full Analysis Set included all participants who were enrolled in the study."}